From time to time, we implement restructuring plans and other cost savings initiatives, which may include workforce

reductions as well as re-balancing of products and services. These restructuring activities are part of our strategic focus on

scaling and re-balancing our cost structure to drive improved profitability.

In the fourth quarter of 2024, we launched initiatives to sunset a product feature used to attract and retain consumers

and healthcare providers to our platform, which included a reduction in force. These initiatives were substantially completed

In the second quarter of 2023, we launched initiatives to de-prioritize certain solutions under our pharma manufacturer

solutions offering. These initiatives were substantially completed as of December 31, 2023.

We did not have any material restructuring related activities in 2022.

The following table summarizes restructuring related costs by type incurred for the years ended December 31, 2024


	Year Ended December 31,
(in thousands)	2024	2023
Non-cash charges (1) (2)	$7,329	$55,723
Cash charges
Personnel related costs (3)	1,993	9,430
Contract costs (4)	566	10,000
Total restructuring related costs	$9,888	$75,153

_____________________________________________________

(1)For the year ended December 31, 2024, non-cash charges principally relate to a $6.8 million loss on disposal of

software license used to support the product feature that was sunset and presented within sales and marketing

expenses in the consolidated statement of operations.

(2)For the year ended December 31, 2023, non-cash charges principally relate to (i) $46.7 million amortization of

acquired intangible assets related to vitaCare and capitalized internal-use software that were accelerated through

December 31, 2023 and presented within depreciation and amortization in the consolidated statement of

operations; and (ii) a $7.0 million loss on the disposal of certain capitalized software that were not yet ready for

their intended use and presented within product development and technology expenses in the consolidated

statement of operations. Non-cash charges also included $1.3 million loss on disposal of allocated goodwill

(3)Cash charges on personnel related costs consist of termination charges arising from severance obligations,

continuation of salaries and benefits over a notification period during which impacted employees did not provide

active service, and other customary employee benefit payments in connection with a reduction in force. For the

year ended December 31, 2024, the majority of these costs were recognized in product development and

technology expenses in the consolidated statement of operations. For the year ended December 31, 2023, $4.5

million of these costs were recognized in cost of revenue, $2.4 million in product development and technology, $2.2

million in sales and marketing with the remainder in general and administrative expenses in the consolidated

(4)For the year ended December 31, 2023, this cash payment relates to the termination of certain contracts with a

pharma manufacturer solutions client, which was recognized as a reduction of revenue in the consolidated

As of December 31, 2024 and 2023, the liability associated with our restructuring related activities was not material.